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Advancements in genetic screening have generatedmassive amounts of data on genetic variation; however, a
lack of clear pathogenic stratification has left most variants classified as being of unknown significance. This
is a critical limitation for translating genetic data into clinical practice. Genetic screening is currently
recommended in the guidelines for diagnosis and treatment of cardiac channelopathies, which are major
contributors to sudden cardiac death in young people. We propose to characterize the pathogenicity of
genetic variants associated with cardiac channelopathies using a stratified scoring system. The development
of this system was considered by using all of the tools currently available to define pathogenicity. The use of
this scoring system could help clinicians to understand the limitations of genetic associations with a disease,
and help them better define the role that genetics can have in their clinical routine.
S udden Cardiac Death. Sudden cardiac death (SCD) is defined as an unexpected and non-traumatic deathof an individual who had been observed healthy in previous 6 hours of the death1. In western countries,SCD underlies 20% of total mortality. Although heart failure and coronary artery disease are the most
prevalent substrates2, epidemiological studies indicate that monogenic syndromes –called inherited
arrhythmogenic diseases- also plays an important role in cardiac electrical instability3. Thus, the inherited
arrhythmogenic diseases have been defined broadly as 2 categories of pathologies: channelopathies and
cardiomyopathies. Channelopathies are caused by pathogenic variations in genes encoding ion channels, and
include Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Short QT Syndrome (SQTS), and
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Cardiomyopathies results from variations
in genes encoding sarcomeric, cytoskeletal, and desmosomal proteins, and include Hypertrophic
Cardiomyopathy (HCM), Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), and Dilated
Cardiomyopathy (DCM).
Significant progress has been made in the identification of a genetic basis of SCD-related disorders. In
particular, next-generation sequencing (NGS) of the human genome has increased dramatically the amount of
genetic data available. Despite this advancement, 2 major genetic challenges in SCD-related diseases remain to be
overcome4. First, amore definite conclusion regarding pathogenicity of variationsmust be reached. Most of the
genetic data, even after bioinformatic evaluation, remains of uncertain significance. In addition, current inter-
national guidelines often focus on the prediction of disease outcomes and/or therapeutic measures only if patients
carry a variant classified as pathogenic5. To our knowledge, few reports have defined pathogenicity and how to
differentiate genetic causality from background noise. For example, a recent study indicated that 30% of disease-
causing genetic variations cited in the literature are common polymorphisms or misinterpreted variants6. Thus,
the second challenge is in translating the genetic data into clinical practice. Clinical interpretation of genetic data
is becoming increasingly complex, and this is particularly true of SCD-related diseases, which are characterized by
incomplete penetrance and variable expressivity and thereby complicate diagnosis and treatment. Current guide-
lines recommend adopting preventive measures depending on both clinical context and family history, but
heritability remains of lower priority5.
If the genetic variations associated with SCD are to be of value in the clinic, their pathogenicitymust be defined.
A recent report describes a methodical assessment that decreases the average time to compile, analyse, and
interpret variant data7. In this report, Duzkale et al. propose several items that should be analysed to classify
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the pathogenicity of each genetic variation. However, they do not
achieve an accurate numeric scale of pathogenicity, thus the patho-
genic classification remains ambiguous. Another recent report high-
lights the current challenges in investigating causality of human
sequence variants, suggesting that each variation be assessed by
combining different tools to determine disease contributions8. In
the present report we propose a scale to stratify pathogenicity for
genetic variations associated with channelopathies. We integrate
multiple parameters to reach a more definite conclusion for use in
the clinic.
Channelopathies. Channelopathies are electrical disorders in struc-
turally normal hearts caused by pathogenic variations in genes
encoding cardiac ionic channels or regulatory proteins. These
alterations modify the ionic balance of the electrical component of
cardiac function and cause life-threatening arrhythmias9.
Long QT syndrome. LQTS is a genetic disorder characterized by a
prolongation of the QT interval on the ECG (QTc . 480 ms). The
clinical presentation can be variable, ranging from asymptomatic to
episodes of syncope and SCD due to ventricular tachyarrhythmia
(torsade de pointes) in the setting of a structurally normal heart.
The syncopal episode may be induced by exertion, and emotional
or auditory stimuli. SCD is the first event in 5% of asymptomatic
LQTS individuals. The estimated prevalence is 1/2500, but the pene-
trance of the disease is not 100%10. In 1993, the first clinical diagnosis
of LQTS was published11. At present, genetic analyses are included in
the scoring criteria for diagnosis5. Thus, individuals and familymem-
bers at risk with a normal ECG may be identified through genetic
testing. Currently, nearly 1200 pathogenic variations have been iden-
tified in 15 genes (KCNQ1, KCNH2, SCN5A,ANK2, KCNE1, KCNE2,
KCNJ2, CACNA1C, CAV3, CALM1, CALM2, SCN4B, AKAP9,
SNTA1, andKCNJ5)12. Combined, these genes contribute to approxi-
mately 80%–85% of all LQT cases. However, 70%–75% of LQT cases
are attributable to pathogenic variations only in 3 genes, KCNQ1
(LQT1), KCNH2 (LQT2), and SCN5A (LQT3), with KCNQ1
responsible for around 35% of cases. Genetic testing for LQTS has
a major role in the diagnosis of index cases, risk stratification, family
screening, and therapeutic strategies, but only for a small number of
pathogenic variations13. Most identified genetic variations remain
untranslated to the clinic.
Brugada syndrome. BrS is an inherited disease described 20 years ago
and characterized by an ECG pattern consisting of coved-type ST-
segment elevation in atypical right-bundle branch block in leads V1 to
V3 (type-1)14. BrS patients have an increased risk for SCD resulting
from episodes of polymorphic ventricular tachyarrhythmia15. BrS
accounts for 4%–12% of overall SCD and 20% of SCDs with normal
hearts. The reported prevalence is 1 to 5/10000 in Europe and 12/
10000 in Southeast Asia, with a ratio of 851 men5women affected. BrS
typically affects young male adults (30–40 years old), and SCD typ-
ically occurs during sleep15. To date, more than 300 pathogenic varia-
tions in 16 genes (SCN5A, GPD1-L, SCN1B, SCN2B, SCN3B, KCNE3,
KCNE5, KCNJ8, KCND3, CACNA1C, CACNB2b, CACNA2D1,
RANGRF, HCN4, SLMAP and TRPM4) have been associated with
BrS16. However, genetic testing only identifies the pathogenic cause
in 35%–40% of clinically diagnosed cases of BrS. Approximately 25%–
30% of diagnosed patients carry a pathogenic variation in the SCN5A
gene17.
Catecholaminergic Polymorphic Ventricular Tachycardia. CPVT is a
familial disease characterized by severe arrhythmias under adrener-
gic stimulation, such as exercise or emotional stress. The resting ECG
is usually normal, but exercise testing induces ventricular arrhythmia
in 75%–100% of patients. In many cases, the first manifestation of
CPVT is the death of the patient. CPVT is associated with high
mortality (around 30% by the age of 30 years), and the estimated
prevalence is 1/1000018. To date, more than 100 pathogenic varia-
tions have been identified in five genes, contributing to nearly 60% of
all clinically diagnosed cases (RYR2, CASQ2, KCNJ2, TRDN,
CALM1, and CALM2). The RYR2 gene, encoding the ryanodine
receptor (autosomal dominant), is responsible for nearly 50% of all
cases12.
Short QT syndrome. First reported in 200019, SQTS is considered the
most lethal channelopathy; it has a high familial incidence of palpita-
tions or syncope, and SCD, typically during childhood, is often the
only phenotypic manifestation. It is characterized by a short QT
interval on the ECG (QTc , 325 ms) with a high sharp T wave20.
The incidence and prevalence are difficult to determine due to lim-
ited data. So far, pathogenic variations have been reported in 4 genes
(KCNQ1, KCNH2, KCNJ2, and CACNA2D1), and these account for
nearly 50% of clinically diagnosed SQT cases12.
Methods
In 2008, the American College of Medical Genetics and Genomics (ACMG) published
guidelines for genetic variant interpretation21. However, most of the genetic tools out-
lined have been improved since 2008, and additional ones have been developed. Most of
the current genetic data generated by high-throughput technologies has identified
exonic common variants previously identified in the general population (minor allele
frequency, MAF . 1%). Much of the remainder is classified as being of unknown
significance, with only a small number of variants classified as pathogenic. To supple-
ment the ACMG guidelines, we propose to incorporate new information to stratify the
level of pathogenicity into 5 groups: pathogenic, probably pathogenic, unknown sig-
nificance, probably non-pathogenic, and non-causal/benign.
Our scale of pathogenicity (Figure 1) is based on the analysis of several items:
- Clinical ascertainment (disease-associated gene or candidate gene) and deter-
mination of the genetic isoform in which the variation was identified;
- Whether the variation has been previously identified in international databases;
- Family segregation (identification of de novo variation may occur); and
- In vitro, in vivo, and in silico evaluation.
We have categorized the scoring using a similar approach to that in the LQTS
Diagnostic Criteria11. Our scores range from 0 to 15 points (Figure 1). Each item
receives a score between 0 and 3 points, and the total of the assessed items determines
whether the exonic genetic variation could be considered pathogenic ($ 12 points),
probably pathogenic (from 9 to 11 points), unknown significance (from 5 to 8 points),
probably non-pathogenic (# 4 points), and benign. This last group comprises genetic
variations considered as common in the global population (MAF . 1%). This fact
implies that our score is useful only for non-silent variants identified in dominant
disorders, in concordance to the diseases assessed in the present report. Finally, before
final genetic interpretation of a variant, it is crucial to know the genetic isoform and
tissue expression in order to perform an appropriate translation into clinical practice.
Results
Clinical ascertainment. The use of genetics as a clinical diagnostic
tool must always consider the context of the clinical case. Therefore,
genetics should complement, and never supplant, the clinical
investigation. The advent of NGS, with its constant discovery of
new associations of genes with diseases, prompts the need for the
confirmation of pathogenicity in more patients and families. This is
especially true in the study of SCD, in which segregation analyses are
limited by the sizes of the families due to the sudden death of some
affected individuals at a young age22. Without a clear clinical
ascertainment, and a clear correlation between the disease and the
genetic variant, causality cannot be conclusive.
Some proportion of the SCD cases arising from unknown genetic
causes could be explained by pathogenic genetic variations in genes
not yet associated with the disease. We hypothesize that the genes
most likely to be associated with such cases are other genes encoding
cardiac ion channels and/or regulatory proteins associated with
them, independently of the cardiac channelopathy diagnosed.
Recently, through the development and improvement of NGS tech-
nologies, several genes previously associated with only one channe-
lopathy have been linked to other channelopathies; for example, the
SCN5A gene contributes to both BrS and LQTS23.
- Genetic variation identified in a disease-related gene 3 points
- Genetic variation identified in a novel gene 2 points
www.nature.com/scientificreports
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(Encoding cardiac ion channels and/or associated regulatory
proteins)
- Genetic variation identified in a novel gene 1 point
(Not encoding cardiac ion channels and/or associated regulatory
proteins)
Genetic databases. Several genetic databases are available, such as
PubMed (www.ncbi.nlm.nih.gov/pubmed), the Exome Variant
Server (http://evs.gs.washington.edu/EVS/), the 1000 Genomes
Project (www.1000genomes.org), and the ClinSeq Project (www.
genome.gov/clinseq). These databases catalog all the genetic data
generated by published large-scale population studies, including
pathogenic, potentially pathogenic, genetic variant of unknown
significance (GVUS), and common genetic variations in the
population. Other databases focus only on potential pathogenic
variations [such as ClinVar (www.clinvar.com) and HGMD (www.
hgmd.cf.ac.uk)]; however, caution should be exercised when
regarding these classifications as not all characterizations are
exhaustive and some of these classified variants could be benign.
We believe that, for each reported pathogenic variation, the
published source should be carefully analysed and interpreted.
Importantly, only if a genetic variation has been reported as
pathogenic inmore than one study could it be suggested as damaging.
In our proposed stratification, this item determines if the variation is
novel (never identified so far) or already reported. If reported, the
variation could be considered pathogenic, of unknown significance, or
neutral/non-causal. In addition, the genetic variation could be classified
as a common (MAF. 1%) or rare (MAF, 1%) variation in the global
population. (MAF , 1% does not imply certain pathogenicity).
- Genetic variation reported in international databases as patho-
genic 3 points
(Minimum of two independent studies)
- Genetic variation reported in international databases as patho-
genic 2 points
(Previously reported as pathogenic only in one study)
- Genetic variation not previously reported in population studies
(Novel) 2 points
(Only if a gene is clearly linked to the functional pathway(s) in
cardiac electrical disorders)
- Genetic variation not previously reported in population studies
(Novel) 1 point
(Gene not clearly linked to cardiac electrical disorders)
- Genetic variation reported in population studies with MAF ,
1% 1 point
One of the main limitations in genetic scenario is the previous
report that a variant is pathogenic. Although there are several genetic
variants already catalogued, recent whole exome/genome studies
have demonstrated a large number of false-positive pathogenic var-
iants that have been incorrectly classified24–26.
Figure 1 | Scale classification workflow. The proposed items should be analysed to classify the variation (gene, variation, family segregation, in vitro, in
vivo, and in silico studies). MAF: Minor Allele Frequency.
www.nature.com/scientificreports
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Family segregation. Family history of syncope/SCD is a significant
risk factor for other syncope/SCD in the family5. For this reason,
familial genetic screening is recommended. However, the lack of
information about pathogenicity of most known genetic variants
implies that genetic screening does not always help to clarify the
risk of syncope/SCD in a family.
In our proposed stratification, familial testing enables discern-
ment of whether a variation is de novo or inherited. If de novo, the
score should be high (2 points) because de novo variations are
strongly associated with pathogenicity27. If a variant is suspected to
be inherited, as many relatives as possible should be tested to clarify
the role of variant. We believe that family segregation is the most
important parameter that helps to clarify a variant’s contribution, but
should not be the only one investigated. For cases inwhich a clinically
affected family member does not carry the potentially pathogenic
variation identified in the index case (negative segregation), the gen-
etic variation could be discarded, or at least ruled out as the main
contributor to the disease, since it could be a modifier of the pheno-
type. If an asymptomatic family member carries the potentially
pathogenic variation, the variation should not be discarded because
of the possibility for incomplete penetrance. Therefore, in our strati-
fication to determine pathogenicity, the presence of a minimum of 5
clinically affected carriers in at least 3 generations28 denotes high
genotype-phenotype correlation (3 points). A lower number of affec-
ted carriers is given a score of 2 points; when the index case alone
carries the variant, 1 point is assigned.
- Familial segregation ($ 5 affected family members in 3 or more
generations) 3 points
- Familial segregation (2 to 4 affected family members or, 3 gen-
erations) 2 points
- Only index case 1 point
- de novo variation 2 points
In vivo studies. Experimental studies in animals are often used to
recapitulate the phenomena underlying both normal and abnormal
human biology. However, both economic and technological
limitations prohibit the development of an animal model for each
genetic variation. In our proposed scale, if an animal model is
available for a variant and it recapitulates the human phenotype
(positive result), 2 points are tallied due to the complexity of
obtaining the data. We have not designated a score of 3 points in
this category because the biological mechanisms exhibited in an
animal model do not faithfully represent the mechanistic
pathway(s) observed in humans. If an animal model is available
but does not recapitulate the human phenotype (negative result)
and/or no model is available, 0 points are given.
- in vivomodel (positive result) 2 points
- in vivomodel (negative result/not available) 0 points
In vitro studies. In vitro studies are one of the main experimental
confirmations of pathogenicity in cardiac channelopathies. However, it
is not feasible to perform in vitro studies to characterize each identified
genetic variation. Even when available, some in vitro functional data
not accurately reflect in vivo physiology29. This phenomenon occurs
because in vitro studies are performed in heterologous systems that do
not include all the necessary biological partners that modify the final
phenotype.
Therefore, in our proposed stratification, if a cellular model is
available for a variant and it mimics the biological mechanism(s)
observed in vivo in humans (positive result), 2 points are tallied. In
particular, ‘‘radical’’ genetic variations (nonsense and indels) have
been assumed as pathogenic/deleterious because the protein will be
altered; in consequence, 2 points are given in all these cases. As with
the animal models, a score of 3 points is excluded from this category
because in vitro studies cannot faithfully reflect the in vivo mech-
anistic pathway(s) in humans. If a cellular model is available but does
not recapitulate the biological mechanism(s) observed in vivo in
humans (negative result) or no model is available, 0 points are given.
- in vitro studies (positive result) or radical variation 2 points
- in vitro studies (negative result/not available) 0 points
In silico studies. Several bioinformatic tools have been developed in
recent years to predict pathogenicity [such as PROVEAN (http://
provean.jcvi.org/index.php), Condel (http://bg.upf.edu/fannsdb/), SIFT
(http://sift.jcvi.org/), Polyphen2 (http://genetics.bwh.harvard.edu/pph2/),
Mutation Taster (www.mutationtaster.org), and Mutation Assessor
(www.mutationassessor.org)]. These computational tools predict the
impact of the genetic variant on the gene/protein sequence, based on
gene alteration, type of variation, protein structure, biochemical
properties of amino acids, and even evolutionary sequence conserva-
tion between species. However, these items are not all included within
one bioinformatic database. In addition, all genetic variations cannot be
found in all bioinformatic databases. Consequently, splicing changes
are identified in specific databases [such as Human Splicing Finder
(http://www.umd.be/HSF/), NNSplice (www.fruitfly.org/seq_tools/splice.
html), and GeneSplicer (www.ccb.jhu.edu/software/genesplicer)],
just as intronic variations are identified in others [such as Alamut
(www.interactive-biosoftware.com/alamut/doc/2.0/splicing.html)].
In our proposed scale, 0 points are assigned if bioinformatic ana-
lyses are not available for a variant in any of the computational
databases, or, if they are available but all in silico analyses showed a
neutral/benign prediction. To include the largest quantity of bioin-
formatic data possible, 2 points are assigned if more than 4 different
databases agree on the predicted pathogenicity (deleterious, prob-
ably, and/or possibly pathogenic) and 1 point if less than 4 databases
agree on the predicted pathogenicity of the variant. This last point
includes, for example, 3 pathogenic and 1 benign, 2 pathogenic and 2
benign, or 4 benign predictions. This threshold is based on the fact
that computational systems do not include all biological elements
existing in humans. Regarding ‘‘radical’’ genetic variations, including
nonsense genetic variations and frameshift/in-frame genetic varia-
tions, no database analyses them because it is assumed that the pro-
tein product will be altered; 2 points are given in all these cases. We
do not assign a score 3 points because an in silico prediction cannot
faithfully reflect a humanmechanistic pathway, and the use of bioin-
formatic tools can produce erroneous conclusions regarding patho-
genicity, as we reported recently30. A positive in silico result means
that pathogenicity is predicted; in contrast, a negative result means
that a neutral/benign variation is predicted.
- in silico (positive result in $ 4 different databases) 2 points
- in silico (positive result in, 4 different databases) 1 point
- in silico (negative result in 4 different databases/not available)
0 points
Discussion
To validate our scale, we analysed several genetic variants localised in
diverse genes associated and non-associated with different channe-
lopathies (Table 1).
For LQTS, we analysed genetic variations localized in two different
genes, KCNQ1 and KCNH2. The first variation analysed was
KCNQ1_p.R452W (c.1354C . T). This genetic variation has been
previously associated with the disease31 -CM055335- (3 points),
reported as pathogenic but only detected in the index case (2 point).
No in vivo or in vitro studies were performed or identified. In silico
analysis revealed four databases with damaging prediction (2 points).
The total score of 8 points in this case indicates that the variant
remains classified as a GVUS; this is in accordance with a recent
report classifyingKCNQ1_p.R452W as a variant of unknown signifi-
www.nature.com/scientificreports
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cance32. Thus, this GVUS should be considered carefully in clinical
practice. We believe that GVUS should be further analysed in rela-
tives, since family segregation and genotype-phenotype correlation
are required to clarify the pathogenic role of a variant.
The second variation was KCNQ1_p.Y315S (c.944A . C), prev-
iously associated with the disease33 -CM970823- (3 points) and
reported as pathogenic in different studies (3 points). Familial segrega-
tion was detected in less than 4 relatives (2 points), and expression of
the variant in rabbit heart produced transgenic rabbits with an LQT
phenotype34 (2 points). In vitro analysis revealed a pathogenic role (2
points), and in silico analysis revealed 4 databases with damaging pre-
diction (2 points). The total score of 14 points supports its classification
as pathogenic in LQTS. In cases in which a pathogenic variation has
been identified, current clinical/genetic guidelines should be followed
both in the index case and in family members.
In KCNH2, also associated with LQTS, we analysed 2 genetic
variations. The first one was KCNH2_p.E58A (c.173A . C), which
was previously associated with the disease35 -CM057129- (3 points),
reported as pathogenic only in one study (2 points), and was detected
only in the index case (1 point). No in vivo or in vitro studies were
identified, and in silico analysis revealed 3 databases with pathogenic
prediction (1 point). The total score of 7 points indicates that the
variant is likely a GVUS. Hence, further studies such as family
segregation and in vivo and/or in vitro analyses should be performed
to clarify its role in LQTS. The last variation associated with LQTS
that we analysed was KCNH2_p.G628S (c.1882G . A), which was
reported to be associated with the disease36 -CM950710- (3 points)
and as pathogenic in more than one study (2 points). Familial
segregation was identified in, 4 relatives (2 points), and expression
in rabbit heart produced transgenic rabbits with an LQT phenotype34
(2 points). In vitro analysis revealed a pathogenic role (2 points), and
in silico analysis revealed 4 databases with damaging prediction (2
points). A total score of 13 points supports the classification of this
variant as pathogenic in LQTS.
For CPVT, 2 variations were analysed. The first one was
RyR2_p.R1013Q (c.3038G. A), previously associated with the dis-
ease37 -CM097930- (3 points) reported as pathogenic but only
detected in the index case (2 point). Familial segregation was iden-
tified only in the index case (1 point) and no in vivo or in vitro studies
were performed. In silico analysis revealed two databases with dam-
aging prediction (1 point). A score of 7 points suggests classification
as a GVUS, in accordance with a recent report32. The second was
RyR2_p.V2475F (c.7423G. T), previously reported associated with
the disease37 -CM097960- (3 points), and with a deleterious effect in
more than one study (3 points). Familial segregation was identified
only in the index case (1 point), and in vivo studies yielded a positive
result (2 points)38. In vitro studies also showed a positive effect (2
points), and in silico analysis revealed 4 databases with damaging
prediction (2 points). The total score of 13 points supports classifica-
tion of this variant as pathogenic in CPVT.
Finally, three variations were analysed for BrS. The first one was
SCN5A_p.V1340I (c.4018G . A), previously associated with the
disease17 -CM100703- (3 points), and with a deleterious effect
reported in only one publication (2 points). It was identified only
in the index case (2 points), and no in vivo studies were performed. In
vitro studies showed a functional effect (2 points), and in silico ana-
lysis revealed three databases with damaging prediction (1 point). A
score of 9 points indicates classification of this variant as probably
pathogenic. Therefore, further studies should be performed to clarify
its role in BrS.
The second variation analysed in BrS was SCN5A_p.R104Q
(c.311G . A), previously reported associated with the disease39 -
CM014904- (3 points), and with a deleterious effect in some studies
(3 points). Positive familial segregation was identified in less than 4
relatives (2 points) but no in vivo studies were performed. In vitro
studies showed a functional effect (2 points), and in silico analysis
revealed four databases with damaging prediction (2 points). The
total score of 12 points indicates pathogenicity.
The last variation showing a disease-association gene was
SCN5A_p.N70K (c.210T . G), previously reported to be associated
with the disease17 -CM100623- (3 points), and with a deleterious
effect but only in one report (2 points). It was identified only in
the index case (1 point), and no in vivo or in vitro studies were
performed. In silico analysis revealed two databases with damaging
prediction (1 point). The total score of 7 points supports classifica-
tion of this variant as a GVUS.
To further assess our scale of pathogenicity, we include some
variation in genes showing a reported association with the disease.
Hence, we analyze PKP2_p.Q62K in a case of suspicious BrS. The
genetic variation is located in a novel gene which encodes a desmo-
somal protein (1 point). The variation is already reported only in one
study as pathogenic (associated with arrhythmogenic cardiomyopa-
thy) (2 points), but only identified in the index case (1 point). Neither
in vivo nor in vitro studies were performed (0 points respectively),
and in silico analysis revealed two databases with damaging predic-
tion (1 point). The total score of 5 points indicates GVUS, in con-
cordance to published studies40.
We also analyzed SCN1Bb_p.P213T in a case of suspicious LQT.
The genetic variation is located in a novel gene which encodes an ion
channel regulatory protein (2 points). The variation is novel but the
gene is linked to functional pathways of cardiac electrical disorders (2
points). No segregation was reported (1 point), and no in vivo studies
are available (0 points). Both in vitro and in silico studies showed
positive results (2 points). Therefore, total score of 9 points indicates
probably pathogenic, as suggested in a recent publication41.
Conclusions
Determining the pathogenic role of genetic variants in channelopa-
thies associated with SCD is necessary for improved clinical dia-
gnosis and therapy of inherited arrhythmogenic diseases. To date,
Table 1 | Examples of the stratified scoring system. LQT: Long QT Syndrome. BrS: Brugada Syndrome. CPVT: Catecholaminergic
Polymorphic Ventricular Tachycardia. GVUS: Genetic Variant Unknown Significance.
Disease Variation Isoform Disease-associated Reported Familial Segregation In vivo In vitro In silico Score Classification of Variant
LQT KCNQ1_p.R452W NM_000218.2 3 2 1 0 0 2 8 GVUS
LQT KCNQ1_p.Y315S NM_000218.2 3 3 2 2 2 2 14 Pathogenic
LQT KCNH2_p.E58A NM_000238.3 3 2 1 0 0 1 7 GVUS
LQT KCNH2_p.G628S NM_000238.3 3 2 2 2 2 2 13 Pathogenic
CPVT RyR2_p.R1013Q NM_001035.2 3 2 1 0 0 1 7 GVUS
CPVT RyR2_p. V2475F NM_001035.2 3 3 1 2 2 2 13 Pathogenic
BrS SCN5A_p.V1340I NM_198056.2 3 2 1 0 2 1 9 Probably Pathogenic
BrS SCN5A_p.R104Q NM_198056.2 3 3 2 0 2 2 12 Pathogenic
BrS SCN5A_p.N70K NM_198056.2 3 1 1 0 0 1 6 GVUS
BrS PKP2_p.Q62K NM_004572.3 1 2 1 0 0 1 5 GVUS
LQT SCN1Bb_p.P213T NM_199037.3 2 2 1 0 2 2 9 Probably Pathogenic
www.nature.com/scientificreports
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most identified genetic variants are considered rare variants of
ambiguous clinical significance.
In the present report we propose a first approach in stratification
of pathogenicity for genetic variations associated with channelopa-
thies. Using several genetic tools available in the biomedical field, we
propose a stratified scale of pathogenicity for variants identified in
genes associated with SCD.We bring togethermultiple well accepted
parameters that should be used together to reach a more definite
clinical conclusion.We believe that this stratificationmay help deter-
mine the pathogenicity of genetic variants and will help clinicians
understand the limitations of genetics and to better decide on thera-
peutic measures to prevent syncopal episodes and SCD.
Limitations
However, some limitations have to be acknowledged in the use of this
approach. First, we propose the scale using several tools, but not all
tools are available for each variant. It is not prudent to classify a
variant using only one of these tools. Second, as genetic information
is progressively becoming available, it is possible that new genetic/
clinical data can change the pathogenicity level in a near future. We
recommend reassessing the results on a regular basis. Finally, expert-
ise is crucial in the handling of the databases and interpretation of the
information. Thus, translation into clinical practice should be per-
formed by consensus of a group of experts in different clinical and
basic disciplines.
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